Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms (NYSE:LLY)

Eli Lilly's strong Q2 results, raised guidance, and robust demand for tirzepatide reinforce confidence in its commercial momentum and market leadership. Learn more about LLY stock here.